
Nice does not recommend Eli Lilly’s lung cancer drug in draft guidance
pharmafile | May 26, 2016 | News story | Research and Development, Sales and Marketing | Cancer Drugs Fund, Eli Lilly, NICE, lung cancer
The National Institute of Care and Excellence (Nice) did not recommend US drugmaker Eli Lilly’s (NYSE: LLY) Portrazza to treat lung cancer saying the therapy cost too much compared to combination chemotherapy.
The appraisal committee also concluded that necitumumab did not meet the criteria to be considered for use in the Cancer Drugs Fund as it was not cost-effective and no clinical uncertainties could be addressed from further data collection.
The regulator in a draft guidance however, acknowledged that necitumumab provides small improvements in overall survival.
Anjali Shukla
Related Content

Cizzle Biotechnology expands US rollout of lung cancer blood test
Cizzle Biotechnology has launched the commercial rollout of its CIZ1B Biomarker Blood Test for lung …

NICE backs atogepant for acute migraine treatment
NICE has issued Final Draft Guidance recommending AbbVie’s AQUIPTA (atogepant) as an option for the …

SMC accepts amivantamab and lazertinib for EGFR-positive lung cancer
The Scottish Medicines Consortium (SMC) has accepted Rybrevant (amivantamab) in combination with Lazcluze (lazertinib) for …






